Barrett's oesophagus — surveillance & management
Barrett's · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Columnar (intestinal) metaplasia of the distal oesophagus from chronic reflux, a premalignant precursor to oesophageal adenocarcinoma. Risk is stratified by segment length and dysplasia grade, which set surveillance intervals and the threshold for endoscopic eradication.
Red flags
- New dysphagia or odynophagia
- Weight loss or iron-deficiency anaemia
- Visible nodule, ulcer or stricture within the segment
- Rapid progression of dysplasia grade
Assessment
Differential diagnosis
- Gastro-oesophageal junction irregularity (non-dysplastic)
- Reflux oesophagitis with pseudo-columnar change
- Eosinophilic oesophagitis
- Oesophageal adenocarcinoma
- Hiatus hernia with columnar-lined lower oesophagus
Investigations
- High-resolution white-light + narrow-band imaging endoscopy
- Seattle protocol biopsies (4-quadrant every 2 cm) plus targeted biopsies of visible lesions
- Prague C&M classification of segment length
- Dysplasia grading by two GI pathologists (confirm any dysplasia)
- FBC/ferritin if bleeding or anaemia
Management
- Confirm true Barrett's: ≥1 cm columnar segment above GOJ with intestinal metaplasia on biopsy
- Document Prague C&M length and photograph/map any visible lesions
- Take Seattle-protocol biopsies plus targeted sampling of mucosal irregularities
- Optimise reflux control with once-daily PPI (symptom and mucosal healing, not chemoprevention proven)
- Risk-stratify: non-dysplastic short segment (<3 cm) vs long segment vs dysplasia
- Non-dysplastic <3 cm with intestinal metaplasia: surveillance every 3–5 years
- Non-dysplastic ≥3 cm: surveillance every 2–3 years
- Indefinite for dysplasia: optimise PPI, repeat endoscopy in 6 months
- Confirmed low-grade dysplasia: refer for endoscopic eradication (radiofrequency ablation) or 6-monthly surveillance if declined
- High-grade dysplasia or intramucosal cancer: endoscopic resection of visible lesions + ablation at expert centre
- Give weight-loss, smoking cessation and reflux lifestyle advice
- Enter into a tracked surveillance register with clear recall
Drugs & doses
Omeprazole 20–40 mg PO once daily
Esomeprazole 40 mg PO once daily (alternative)
Lansoprazole 30 mg PO once daily (alternative)
Disposition
Outpatient GI surveillance clinic with structured recall; refer dysplasia/early cancer to a Barrett's/upper-GI MDT at an expert endotherapy centre.
Complications & pitfalls
- Oesophageal adenocarcinoma
- Post-ablation stricture
- Bleeding or perforation after endoscopic resection
- Buried/recurrent intestinal metaplasia
Exam pearls
- Intestinal metaplasia on biopsy is required for the diagnosis in most guidelines — not columnar appearance alone
- Any dysplasia must be confirmed by a second expert GI pathologist before acting
- Endoscopic eradication is now standard for confirmed low-grade dysplasia, not just high-grade
- Do not biopsy during active oesophagitis — treat with PPI and re-scope
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.